FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260397345> ?p ?o ?g. }

• W2260397345 endingPage "14040" @default.
• W2260397345 startingPage "14040" @default.
• W2260397345 abstract "14040 Background: We are conducting a phase II trial of the proteasome inhibitor, PS-341, with or without irinotecan in pts with AGA. The combination of PS-341 and irinotecan has been studied in preclinical tumor models including a murine xenograft model of colon cancer, where the combination achieved significantly more tumor shrinkage than either agent alone. The primary objective of this study is to determine response rates, toxicities, progression-free survival, and overall survival in pts with AGA receiving PS-341 alone or in combination with irinotecan. Methods: All pts had gastric adenocarcinoma beyond the scope of surgical resection, measurable disease, and normal bone marrow, hepatic and renal function. All gave informed consent. In previously untreated patients, PS-341 was administered at 1.3 mg/m 2 on days 1, 4, 8, and 11 as IV bolus every 21 days. Irinotecan was administered IV at 125 mg/m 2 over 90 mins on days 1 and 8 every 21 days (Arm A). For previously treated patients, PS-341 was administered as a single agent at 1.3mg/m 2 on days 1, 4, 8, 11 as an IV bolus every 21 days (Arm B). Radiologic evaluation and tumor measurements were performed every 8 weeks. Results: Thirty-seven pts have been enrolled; 29 are evaluable (4 never treated, 4 TETE). Twenty-two pts were treated in Arm A, and 11 in Arm B. All pts were eligible and the 29 treated pts were fully evaluable. Median age 58 (33–87); 26 males/7 females; median number of cycles received was 2.0. Most common toxicities: Grade 4 cardiac arrest (1), stomach perforation (1), leukopenia (2), diarrhea (1), edema (1); Grade 3 nausea (6), vomiting (7), diarrhea (4), febrile neutropenia (3), thrombocytopenia (6), anemia (6); Grade 5 death (3). Severe toxicities likely attributed to disease progression. Response rate was 33% for Arm A, 9% for Arm B. Progression-free survival was 1.8 mo. in Arm A, 1.4 mo. in Arm B. Median overall survival was 4.8 mo. in Arm A, 5.4 mo. in Arm B. Conclusions: The combination of PS-341 and irinotecan, a non-cisplatin containing therapy, is active in AGA and should be considered a key regimen. Monotherapy with PS-341 has a 9% response rate in this population of pre-treated patients with advanced disease. Accrual to this study is continuing. [Table: see text]" @default.
• W2260397345 created "2016-06-24" @default.
• W2260397345 creator A5016023883 @default.
• W2260397345 creator A5023286193 @default.
• W2260397345 creator A5027165899 @default.
• W2260397345 creator A5034382115 @default.
• W2260397345 creator A5035457449 @default.
• W2260397345 creator A5045890712 @default.
• W2260397345 creator A5049924653 @default.
• W2260397345 creator A5059375706 @default.
• W2260397345 creator A5065354635 @default.
• W2260397345 creator A5071579916 @default.
• W2260397345 date "2006-06-20" @default.
• W2260397345 modified "2023-10-16" @default.
• W2260397345 title "Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)" @default.
• W2260397345 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.14040" @default.
• W2260397345 hasPublicationYear "2006" @default.
• W2260397345 type Work @default.
• W2260397345 sameAs 2260397345 @default.
• W2260397345 citedByCount "14" @default.
• W2260397345 countsByYear W22603973452012 @default.
• W2260397345 countsByYear W22603973452013 @default.
• W2260397345 countsByYear W22603973452015 @default.
• W2260397345 countsByYear W22603973452019 @default.
• W2260397345 crossrefType "journal-article" @default.
• W2260397345 hasAuthorship W2260397345A5016023883 @default.
• W2260397345 hasAuthorship W2260397345A5023286193 @default.
• W2260397345 hasAuthorship W2260397345A5027165899 @default.
• W2260397345 hasAuthorship W2260397345A5034382115 @default.
• W2260397345 hasAuthorship W2260397345A5035457449 @default.
• W2260397345 hasAuthorship W2260397345A5045890712 @default.
• W2260397345 hasAuthorship W2260397345A5049924653 @default.
• W2260397345 hasAuthorship W2260397345A5059375706 @default.
• W2260397345 hasAuthorship W2260397345A5065354635 @default.
• W2260397345 hasAuthorship W2260397345A5071579916 @default.
• W2260397345 hasConcept C121608353 @default.
• W2260397345 hasConcept C126322002 @default.
• W2260397345 hasConcept C126894567 @default.
• W2260397345 hasConcept C141071460 @default.
• W2260397345 hasConcept C2780259306 @default.
• W2260397345 hasConcept C2781182431 @default.
• W2260397345 hasConcept C29730261 @default.
• W2260397345 hasConcept C31760486 @default.
• W2260397345 hasConcept C43376680 @default.
• W2260397345 hasConcept C526805850 @default.
• W2260397345 hasConcept C71924100 @default.
• W2260397345 hasConcept C90924648 @default.
• W2260397345 hasConceptScore W2260397345C121608353 @default.
• W2260397345 hasConceptScore W2260397345C126322002 @default.
• W2260397345 hasConceptScore W2260397345C126894567 @default.
• W2260397345 hasConceptScore W2260397345C141071460 @default.
• W2260397345 hasConceptScore W2260397345C2780259306 @default.
• W2260397345 hasConceptScore W2260397345C2781182431 @default.
• W2260397345 hasConceptScore W2260397345C29730261 @default.
• W2260397345 hasConceptScore W2260397345C31760486 @default.
• W2260397345 hasConceptScore W2260397345C43376680 @default.
• W2260397345 hasConceptScore W2260397345C526805850 @default.
• W2260397345 hasConceptScore W2260397345C71924100 @default.
• W2260397345 hasConceptScore W2260397345C90924648 @default.
• W2260397345 hasIssue "18_suppl" @default.
• W2260397345 hasLocation W22603973451 @default.
• W2260397345 hasOpenAccess W2260397345 @default.
• W2260397345 hasPrimaryLocation W22603973451 @default.
• W2260397345 hasRelatedWork W1974123654 @default.
• W2260397345 hasRelatedWork W2010125764 @default.
• W2260397345 hasRelatedWork W2027936171 @default.
• W2260397345 hasRelatedWork W2052181765 @default.
• W2260397345 hasRelatedWork W2188608911 @default.
• W2260397345 hasRelatedWork W2246109806 @default.
• W2260397345 hasRelatedWork W2381201307 @default.
• W2260397345 hasRelatedWork W2462440291 @default.
• W2260397345 hasRelatedWork W32832981 @default.
• W2260397345 hasRelatedWork W4238982852 @default.
• W2260397345 hasVolume "24" @default.
• W2260397345 isParatext "false" @default.
• W2260397345 isRetracted "false" @default.
• W2260397345 magId "2260397345" @default.
• W2260397345 workType "article" @default.